Rights statement: This is the peer reviewed version of the following article: Dauvermann, M. R., Lee, G., and Dawson, N. (2017) Glutamatergic regulation of cognition and functional brain connectivity: insights from pharmacological, genetic and translational schizophrenia research. British Journal of Pharmacology, 174: 3136–3160. doi: 10.1111/bph.13919 which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/bph.13919/abstract This article may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Accepted author manuscript, 361 KB, PDF document
Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
| <mark>Journal publication date</mark> | 10/2017 |
|---|---|
| <mark>Journal</mark> | British Journal of Pharmacology |
| Issue number | 19 |
| Volume | 174 |
| Number of pages | 25 |
| Pages (from-to) | 3136-3160 |
| Publication Status | Published |
| Early online date | 11/08/17 |
| <mark>Original language</mark> | English |
The pharmacological modulation of glutamatergic neurotransmission to improve cognitive function has been a focus of intensive research, particularly in relation to the cognitive deficits seen in schizophrenia. Despite this effort there has been little success in the clinical use of glutamatergic compounds as procognitive drugs. Here we review a selection of the drugs used to modulate glutamatergic signalling and how they impact on cognitive function in rodents and humans. We highlight how glutamatergic dysfunction, and NMDA receptor hypofunction in particular, is a key mechanism contributing to the cognitive deficits observed in schizophrenia, and outline some of the glutamatergic targets that have been tested as putative procognitive targets for the disorder. Using translational research in this area as a leading exemplar, namely models of NMDA receptor hypofunction, we discuss how the study of functional brain network connectivity can provide new insight into how the glutamatergic system impacts on cognitive function. Future studies characterising functional brain network connectivity will increase our understanding of how glutamatergic compounds regulate cognition and could contribute to the future success of glutamatergic drug validation.